Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

The study is being conducted to evaluate the safety, tolerability and efficacy of HRS-4642 combined with adebrelimab, or with adebrelimab and other antitumor agents in patients with advanced pancreatic ductal adenocarcinoma (PDAC).

Trial Details

NCT ID
NCT06427239
Phase
PHASE1 / PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HRS-4642
  • Adebrelimab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients volunteered to participate in this study and signed informed consent;
  • Age: ≥18 and ≤75 years old, male or female;
  • Advanced (metastatic or unresectable) Pancreatic ductal adenocarcinoma; and subjects must have at least one measurable lesion as defined by RECIST …
  • With failure or absence of standard treatment, and progress within 6 months of adjuvant therapy can also be included in the study;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →